Zack Newton

Carbon Engineering (CE) is a Canadian-based clean energy company leading the commercialization of groundbreaking technology that captures CO₂ directly from air, and a second technology that synthesizes it into clean, affordable transportation fuels. For job postings visit carbonengineering.com/careers

Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company is developing new proprietary small molecule therapeutic candidates with the intention of developing best-in-class therapeutics for the treatment of unmet metabolic, inflammatory and fibrotic diseases, using its integrated drug discovery platform, expertise in medicinal chemistry and deep understanding of GPCR biology. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/

Wittington Investments, Limited, a private Canadian company, is the holding company of the Weston group of companies, which includes George Weston Limited, Loblaw Companies Limited and Choice Properties REIT. George Weston Limited is a Canadian public company, founded in 1882. George Weston has two operating segments: Loblaw Companies Limited, Canada’s largest food and drug retailer and a provider of financial services, and Choice Properties Real Estate Investment Trust, Canada’s largest and preeminent diversified REIT. With over 200,000 employees working at George Weston and its operating segments, the group of companies represent one of Canada’s largest private sector employers.

Carbon Engineering (CE) is a Canadian-based clean energy company leading the commercialization of groundbreaking technology that captures CO₂ directly from air, and a second technology that synthesizes it into clean, affordable transportation fuels. For job postings visit carbonengineering.com/careers

Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company is developing new proprietary small molecule therapeutic candidates with the intention of developing best-in-class therapeutics for the treatment of unmet metabolic, inflammatory and fibrotic diseases, using its integrated drug discovery platform, expertise in medicinal chemistry and deep understanding of GPCR biology. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/